What Does the Future Hold for Long Acting Injectable PrEP?

With long-acting injectable PrEP coming to market, how can we mitigate barriers and adopt the intervention widely in high-risk settings? On Wednesday, November 10, Evidence to Action, the webinar series hosted by the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), heard from experts at Johns Hopkins University, United States Agency for International Development (USAID), AVAC, Asia Pacific Coalition on Male Sexual Health (APCOM), and EGPAF on what’s new in PrEP, the present and future of long-acting injectables, what actions to take for optimal implementation and how we can better enable access in key populations.

Speakers to Include:

• Opening Remarks: Anja Giphart, EGPAF


• An overview of long-acting technologies and strategies in development for PrEP: Charles Flexner, Johns Hopkins University of Medicine


• Reflecting on implementation of biomedical prevention interventions to date in the context of implementation of long-acting injectables and new products: Robyn Eakle, USAID


• Priority actions to enable uptake of new products: Mitchell Warren, AVAC


• How this will effect key populations and how we work alongside key pops to drive awareness around technical and practical aspects: Midnight Poonkasetwatana, APCOM


• Concerns about making long term decisions on medication in the postpartum period: Dee Mphafi, EGPAF Youth Advocate


• Moderated Discussion: Natella Rakhmanina, EGPAF

Downloads:

• Recording
• Mitchell Warren's Slides